Bladder Neoplasms Clinical Trial
Official title:
A Cross-Sectional Study Of Patient-Reported Outcomes For Bladder Cancer Patients With Non-Invasive Disease
The purpose of this study is to identify aspects of the bladder cancer (BlCa) survivorship experience that differ by clinical risk at diagnosis. The investigators will collect cross-sectional data from persons with BlCa to identify aspects of health-related quality of life (HRQOL) and symptom management. The study originally enrolled only nonmuscle-invasive bladder cancer survivors but has been expanded to include survivors with any stage disease. Information from this study will be used to develop a new patient education and counseling intervention.
n/a
Observational Model: Cohort, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00536588 -
A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)
|
Phase 1 | |
| Recruiting |
NCT00872495 -
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
|
||
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Completed |
NCT00406068 -
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00077688 -
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
|
Phase 2 | |
| Completed |
NCT00462488 -
Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ
|
Phase 2 | |
| Completed |
NCT00001381 -
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
|
Phase 1 | |
| Terminated |
NCT00050687 -
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00343356 -
Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder
|
Phase 2 | |
| Completed |
NCT00315237 -
Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract
|
Phase 3 | |
| Completed |
NCT00141531 -
Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
|
Phase 2 | |
| Completed |
NCT00491114 -
Intravesical Chemotherapy Treatment of Superficial Bladder Cancer
|
Phase 2 | |
| Completed |
NCT00393809 -
Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00101608 -
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
|
Phase 2 | |
| Terminated |
NCT00191477 -
Instillation of Gemcitabine in Patients With Superficial Bladder Cancer
|
Phase 3 | |
| Recruiting |
NCT05072600 -
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
|
Phase 2 | |
| Completed |
NCT00963404 -
Image-Guided Tumorboost of Bladder Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00109655 -
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
|
Phase 1 | |
| Completed |
NCT00188695 -
Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00871754 -
Molecular Analysis Of Bladder Cancer
|